120 related articles for article (PubMed ID: 29696637)
21. Prostatic specific antigen and bone scan in the diagnosis and follow-up of prostate cancer. Can diagnostic significance of PSA be increased?
Bantis A; Grammaticos P
Hell J Nucl Med; 2012; 15(3):241-6. PubMed ID: 23227460
[TBL] [Abstract][Full Text] [Related]
22. Determination of the percentage of free prostate-specific antigen helps to avoid unnecessary biopsies in men with normal rectal examinations and total prostate-specific antigen of 4-10 ng/ml.
Martínez-Piñeiro L; Tabernero A; Contreras T; Madero R; Lozano D; López-Tello J; Alonso-Dorrego JM; Picazo ML; González Gancedo P; Martínez-Piñeiro JA; de La Peña JJ
Eur Urol; 2000 Mar; 37(3):289-96. PubMed ID: 10720854
[TBL] [Abstract][Full Text] [Related]
23. Prostate-Specific Antigen (PSA)-Based Population Screening for Prostate Cancer: An Economic Analysis.
Tawfik A
Ont Health Technol Assess Ser; 2015; 15(11):1-37. PubMed ID: 26366237
[TBL] [Abstract][Full Text] [Related]
24. Prostate-specific antigen kinetics in screen-detected prostate cancer in Japan.
Takechi H; Ito K; Yamamoto T; Miyakubo M; Ohi M; Suzuki K
Urology; 2008 Nov; 72(5):1111-5. PubMed ID: 18342926
[TBL] [Abstract][Full Text] [Related]
25. [Advantages and risks of the use of prostate-specific antigen (PSA) in the health-care area No. 4 of Gijon (Asturias)].
Cepeda Piorno J; Rivas del Fresno M; Fuente Martín E; González García E; Muruamendiaraz Fernández V; Fernández Rodríguez E
Arch Esp Urol; 2005 Jun; 58(5):403-11. PubMed ID: 16078781
[TBL] [Abstract][Full Text] [Related]
26. Age-Adjusted PSA Levels in Prostate Cancer Prediction: Updated Results of the Tyrol Prostate Cancer Early Detection Program.
Heidegger I; Fritz J; Klocker H; Pichler R; Bektic J; Horninger W
PLoS One; 2015; 10(7):e0134134. PubMed ID: 26218594
[TBL] [Abstract][Full Text] [Related]
27. Cumulative probability of PSA increase above 4.0 NG/ML in population-based screening for prostate cancer.
Ito K; Yamamoto T; Ohi M; Takechi H; Kurokawa K; Suzuki K; Yamanaka H
Int J Cancer; 2004 Apr; 109(3):455-60. PubMed ID: 14961587
[TBL] [Abstract][Full Text] [Related]
28. Estimating the sensitivity of a prostate cancer screening programme for different PSA cut-off levels: A UK case study.
Leal J; Welton NJ; Martin RM; Donovan J; Hamdy F; Neal D; Noble S; Lane A; Wolstenholme J
Cancer Epidemiol; 2018 Feb; 52():99-105. PubMed ID: 29278842
[TBL] [Abstract][Full Text] [Related]
29. Clinical significance of prostate specific antigen for early stage prostate cancer detection.
Imai K; Ichinose Y; Kubota Y; Yamanaka H; Sato J; Saitoh M; Watanabe H; Ohe H
Jpn J Clin Oncol; 1994 Jun; 24(3):160-5. PubMed ID: 7516445
[TBL] [Abstract][Full Text] [Related]
30. [Screening for early detection of prostate cancer (first experience in Israel)].
Neheman A; Shotland Y; Metz Y; Stein A
Harefuah; 2001 Jan; 140(1):4-10, 88, 87. PubMed ID: 11242898
[TBL] [Abstract][Full Text] [Related]
31. A continuous fall of PSA use for prostate cancer screening among Brazilian doctors since 2001. Good or bad notice?
Araújo FAGDR; Sumita NM; Barroso UO
Int Braz J Urol; 2019; 45(3):478-485. PubMed ID: 31038862
[TBL] [Abstract][Full Text] [Related]
32. American Urological Association (AUA) guideline on prostate cancer detection: process and rationale.
Carter HB
BJU Int; 2013 Sep; 112(5):543-7. PubMed ID: 23924423
[TBL] [Abstract][Full Text] [Related]
33. Screening for Prostate Cancer Starting at Age 50-54 Years. A Population-based Cohort Study.
Carlsson S; Assel M; Ulmert D; Gerdtsson A; Hugosson J; Vickers A; Lilja H
Eur Urol; 2017 Jan; 71(1):46-52. PubMed ID: 27084245
[TBL] [Abstract][Full Text] [Related]
34. [Current results on PSA-based prostate cancer detection].
Graefen M; Schlomm T; Steuber T; Sauter G
Bundesgesundheitsblatt Gesundheitsforschung Gesundheitsschutz; 2014 Mar; 57(3):312-7. PubMed ID: 24562706
[TBL] [Abstract][Full Text] [Related]
35. The Finnish prostate cancer screening trial: analyses on the screening failures.
Kilpeläinen TP; Tammela TL; Malila N; Hakama M; Santti H; Määttänen L; Stenman UH; Kujala P; Auvinen A
Int J Cancer; 2015 May; 136(10):2437-43. PubMed ID: 25359457
[TBL] [Abstract][Full Text] [Related]
36. Screening for prostate cancer--how to manage in 2006?
Lobel B
Acta Chir Iugosl; 2005; 52(4):19-21. PubMed ID: 16673588
[TBL] [Abstract][Full Text] [Related]
37. Deliberative democracy and cancer screening consent: a randomised control trial of the effect of a community jury on men's knowledge about and intentions to participate in PSA screening.
Thomas R; Glasziou P; Rychetnik L; Mackenzie G; Gardiner R; Doust J
BMJ Open; 2014 Dec; 4(12):e005691. PubMed ID: 25539779
[TBL] [Abstract][Full Text] [Related]
38. Determination of serum prostate-specific antigen-alpha1-antichymotrypsin complex for diagnosis of prostate cancer in Japanese cases.
Kuriyama M; Abrahamsson PA; Imai K; Akimoto S; Deguchi N; Shichiri Y; Sugiyama Y; Niwa T; Inoue T
Scand J Urol Nephrol; 2001 Feb; 35(1):5-10. PubMed ID: 11291689
[TBL] [Abstract][Full Text] [Related]
39. Circulating Prostate-Specific Antigen and Telomere Length in a Nationally Representative Sample of Men Without History of Prostate Cancer.
Wulaningsih W; Astuti Y; Matsuguchi T; Anggrandariyanny P; Watkins J;
Prostate; 2017 Jan; 77(1):22-32. PubMed ID: 27566127
[TBL] [Abstract][Full Text] [Related]
40. Use of low free to total PSA ratio in prostate cancer screening: detection rates, clinical and pathological findings in Brazilian men with serum PSA levels <4.0 ng/mL.
Faria EF; Carvalhal GF; dos Reis RB; Tobias-Machado M; Vieira RA; Reis LO; Nogueira L; Machado RD; Freitas CH; Magnabosco WJ; Mauad EC; Carvalho AL
BJU Int; 2012 Dec; 110(11 Pt B):E653-7. PubMed ID: 22892057
[TBL] [Abstract][Full Text] [Related]
[Previous] [Next] [New Search]
